Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Genetic variation associated with cardiovascular risk in autoimmune diseases

  • Perrotti, Pedro P.
  • Aterido, Adrià|||0000-0003-1810-410X
  • Fernández-Nebro, Antonio|||0000-0002-2962-9844
  • Cañete, Juan D.|||0000-0003-2606-0573
  • Ferrándiz, Carlos|||0000-0001-9030-8399
  • Tornero, Jesús
  • P. Gisbert, Javier|||0000-0003-2090-3445
  • Domènech, Eugeni|||0000-0002-2315-7196
  • Fernández-Gutiérrez, Benjamín
  • Gomollón, Fernando|||0000-0003-0076-3529
  • García-Planella, Esther|||0000-0002-4325-0697
  • Fernández, Emilia
  • Sanmartí, Raimon|||0000-0002-8864-3806
  • Gratacós, Jordi|||0000-0003-4007-4103
  • Martínez-Taboada, Víctor Manuel
  • Rodríguez-Rodríguez, Luís
  • Palau, Núria
  • Tortosa, Raúl
  • Corbeto, Mireia L.
  • Lasanta, María L.
  • Marsal, Sara|||0000-0001-5515-3854
  • Julià Cano, Antonio|||0000-0001-6064-3620
Autoimmune diseases have a higher prevalence of cardiovascular events compared to the general population. The objective of this study was to investigate the genetic basis of cardiovascular disease (CVD) risk in autoimmunity. We analyzed genome-wide genotyping data from 6,485 patients from six autoimmune diseases that are associated with a high socioeconomic impact. First, for each disease, we tested the association of established CVD risk loci. Second, we analyzed the association of autoimmune disease susceptibility loci with CVD. Finally, to identify genetic patterns associated with CVD risk, we applied the crossphenotype meta-analysis approach (CPMA) on the genome-wide data. A total of 17 established CVD risk loci were significantly associated with CVD in the autoimmune patient cohorts. From these, four loci were found to have significantly different genetic effects across autoimmune diseases. Six autoimmune susceptibility loci were also found to be associated with CVD risk. Genome-wide CPMA analysis identified 10 genetic clusters strongly associated with CVD risk across all autoimmune diseases. Two of these clusters are highly enriched in pathways previously associated with autoimmune disease etiology (TNFα and IFNγ cytokine pathways). The results of this study support the presence of specific genetic variation associated with the increase of CVD risk observed in autoimmunity.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A combined transcriptomic and genomic analysis identifies a gene signature associated with the response to anti-TNF therapy in rheumatoid arthritis

  • Aterido, Adrià|||0000-0003-1810-410X
  • Cañete, Juan D.|||0000-0003-2606-0573
  • Tornero, Jesús
  • Blanco-García, F.J.|||0000-0001-9821-7635
  • Fernández-Gutiérrez, Benjamín
  • Pérez-García, Carolina|||0000-0002-6695-6406
  • Alperi-López, Mercedes
  • Olivé Marqués, Alejandro|||0000-0002-6707-8043
  • Corominas, Hèctor|||0000-0002-7738-6787
  • Martínez-Taboada, Víctor
  • González, Isidoro
  • Fernández-Nebro, Antonio|||0000-0002-2962-9844
  • Erra Duran, Alba|||0000-0001-7806-1098
  • López Lasanta, María|||0000-0002-8462-8406
  • López-Corbeto, Mireia|||0000-0003-1166-1456
  • Palau, Núria
  • Marsal, Sara|||0000-0001-5515-3854
  • Julià Cano, Antonio|||0000-0001-6064-3620
Background: Rheumatoid arthritis (RA) is the most frequent autoimmune disease involving the joints. Although anti-TNF therapies have proven effective in the management of RA, approximately one third of patients do not show a significant clinical response. The objective of this study was to identify new genetic variation associated with the clinical response to anti-TNF therapy in RA. Methods: We performed a sequential multi-omic analysis integrating different sources of molecular information. First, we extracted the RNA from synovial biopsies of 11 RA patients starting anti-TNF therapy to identify gene coexpression modules (GCMs) in the RA synovium. Second, we analyzed the transcriptomic association between each GCM and the clinical response to anti-TNF therapy. The clinical response was determined at week 14 using the EULAR criteria. Third, we analyzed the association between the GCMs and anti-TNF response at the genetic level. For this objective, we used genome-wide data from a cohort of 348 anti-TNF treated patients from Spain. The GCMs that were significantly associated with the anti-TNF response were then tested for validation in an independent cohort of 2,706 anti-TNF treated patients. Finally, the functional implication of the validated GCMs was evaluated via pathway and cell type epigenetic enrichment analyses. Results: A total of 149 GCMs were identified in the RA synovium. From these, 13 GCMs were found to be significantly associated with anti-TNF response (P < 0.05). At the genetic level, we detected two of the 13 GCMs to be significantly associated with the response to adalimumab (P = 0.0015) and infliximab (P = 0.021) in the Spain cohort. Using the independent cohort of RA patients, we replicated the association of the GCM associated with the response to adalimumab (P = 0.0019). The validated module was found to be significantly enriched for genes involved in the nucleotide metabolism (P = 2.41e-5) and epigenetic marks from immune cells, including CD4+ regulatory T cells (P = 0.041). Conclusions: These findings show the existence of a drug-specific genetic basis for anti-TNF response, thereby supporting treatment stratification in the search for response biomarkers in RA.